Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to ...

As it is now, the transplant system treats kidneys from all Black donors as if they are at higher risk for failing, even though only some are.

Maze Therapeutics (MAZE) announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in ...

Each year around 1,000 people choose to donate one of their kidneys - people with two parents of Black African and Black ...

Kidney disease affects millions of Americans, with Black communities facing disproportionately higher risks due to genetic factors, socioeconomic challenges, ...

The NHS has launched a new genetic blood test to improve the safety of kidney donations from people of Black African and ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

Following APOL1 testing, those shown to be at high risk of developing kidney failure later in life, and who are under 60 ...

Approximately 160 tests are set to be conducted annually by the NHS to screen for 'high-risk' genetic variants.

Hundreds of potential kidney donors of Black African and Black Caribbean heritage can now access a simple blood test designed ...